摘要
目的探讨紫杉醇加顺铂(TP方案)的新辅助化疗对提高ⅢA期非小细胞肺癌(NSCLC)手术切除率的影响。方法50例ⅢA期NSCLC患者随机分为新辅助化疗组(25例)和单纯手术组(25例)。新辅助化疗患者确诊后即接受2个周期全身化疗后手术,单纯手术组患者确诊后直接手术治疗。结果新辅助化疗组手术切除率为99.0%(24/25),根治切除率为64.0%(16/25);单纯手术组手术切除率为76.0(19/25),根治切除率为28.0%(7/25)。新辅助化疗组手术切除率和根治性切除率明显高于单纯手术组患者(P<0.05)。新辅助化疗并未增加手术并发症。结论新辅助化疗可明显提高ⅢA期NSCLC患者手术切除率和根治切除率。
Objective To investigate the effect of neoadjuvent chomotherapy of paclitexel plus eisplatin for improving the surgical resection rate of stage Ⅲ A non-small cell lung cancer（NSCLC）. Methods 46 patients with stage Ⅲ A NSCLC were randomly divided into neoadjuvant chemotherapy group（25 caeses） and simple operative group（25 cases）. Neoedjuvant chemotherapy group（NCG） received two-cycle chemotherapy and then underwent operation. Simple operative group（SOG） was only treated by operation. Results The operative resection rate of NCG was 99.0 %, radical resection rate was 64.0 %. It was higher obviously than that simple operative group（SOG）（ P 〈 0.05）. The operative resection rate and radical resection rate of were 76.0 % and 28.0 % respectively in the latter group. The operative compllcatlans did not increase in the NCG. Conclusion The neoadjuvant chemotherapy can improve obviously the operative resection rate and radical resection for patients with NSCLC.
出处
《中国基层医药》
CAS
2006年第2期201-202,共2页
Chinese Journal of Primary Medicine and Pharmacy
